- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05886517
Transfemoral Transcatheter Aortic Valve Implementation at Hospital Without On-site Cardiac Surgery: Early Clinical Outcome in Patients With Prohibitive Surgical Risk.
May 23, 2023 updated by: AUSL Romagna Rimini
Study design: single arm, interventional and multicenter study.
The objectives are evaluate Safety and efficacy of TAVI in Department of Cardiology without on site cardiac Surgery for symptomatic severe aortic valve stenosis by expert operator team, in patients with prohibitive surgical risk.
For the pilot phase, 20 patients will be enrolled.
For whole study, all consecutive patients undergoing TAVI in center without CS on site will be enrolled to reach a number of about 200 patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fabio Tarantino, Medical Director
- Phone Number: 0543735132
- Email: fabio.tarantino@auslromagna.it
Study Contact Backup
- Name: Miriam Compagnone
- Phone Number: 0543735132
Study Locations
-
-
Emilia Romagna
-
Forli, Emilia Romagna, Italy, 47121
- Recruiting
- AUSL Romagna Morgagni - Pierantoni Hospital
-
Contact:
- Fabio Tarantino, MD, MSc
- Email: fabio.tarantino@auslromagna.it
-
Principal Investigator:
- Fabio P Tarantino, MD
-
Sub-Investigator:
- Miriam Compagnone, MD, MSc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient > 40 mmHg or jet velocity > 4.0 m/s aortic valve area (AVA) of < 0.8 cm2 (or AVA index < 0.5 cm2/m2)
- Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class > = II
- Age >= 75 years old
- Patients with prohibitive risk established in the Heart Team and defined on the basis of the following clinica instrument criteria according with the Varc-2 consensus.
- High surgical risk (%, logES>20%, EuroSCORE II > 9 and STS score > 8%)
- Porcelain aorta (heavy circumferential calcification or severe atheromatous plaques that do not allow clamping.
- Hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis or other skeletal abnormalities, complications form to previous surgery, evidence of severe radiotion damege, history of multiple recurrent pleural effusions causing internal adhesions.
- Fragilty (slowness, weakness, exhaustion, wasting and malnutrition, poor endurance and inactivity, loss of independence, BMI < 20 Kg/m2 and or weight loss 5 kg/year, serum albumin < 3,5 g/dl, cognitive impairment or dementia)
- Severe liver disease/cirrosis
- Presence of a patent graft of an internal mammary artery crossing mildline and/or adherent to posterior table of sternum
- Severe pulmoary hypertension
- Severe right ventricular dysfunction
- Transfemoral access allowed
- Signature of informed consent
Exclusion Criteria:
- Tavi in case of aortic valve bioprosthesis (TAVI valve-in valve)
- controindication to femoral access
- Bicuspid aortic valve
- Instrumental characteristics, evaluated by angioTC, associated with an increased risk of major complications: severe left ventricle outflow tract or sub annular calcification, condition associated with an increased risk of rupture of the valve ring, presence of complex aortic plaques correlated with the possibility of dissection, valvular ring-coronary ostia distance < 10 mm associated with a high probability of coronary obstruction, severe aortic root dilatation or out of range aortic annulus diameters for TAVI are not complatible for safe valve implatation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAVI procedure
Patients will be evaluated at baseline to access their eligibility for the procedure.
The day of TAVI patients will be prepared for the procedures as the institution's standard practice for an invasive percutaneous endovascular procedure.
During the pre hospital discharge period, patients will be monitored and will receive standard post-procedure care as judged appropriate by PI.
At 30 days from the procedure a Fu visit will be made in order to access survival and adverse clinical events.
|
ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide.
The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve.
Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of all cause death patients in 30 days following TAVI/total TAVI patients
Time Frame: 4 weeks
|
the simple size calculation is based on the primary endpoint mortality at 30 days.
Considering a standard incidence of 6-7% 200 patients will be needed to demonstrate, wuth an alpha error of 5% the non inferiority of the alternative treatment compared to the standard considering a non inferiory margin of 3% such as to exclude mortaluty values higher than 10%, in relation at the upper limit of the 90% confidence interval calculated with the exact method of clopper and Pearson.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2023
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
May 12, 2023
First Submitted That Met QC Criteria
May 23, 2023
First Posted (Estimated)
June 2, 2023
Study Record Updates
Last Update Posted (Estimated)
June 2, 2023
Last Update Submitted That Met QC Criteria
May 23, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAVI at Home
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting
Clinical Trials on Transfemoral transcatheter aortic valve implementation
-
Dr. Giuseppe MusumeciNot yet recruitingTransfemoral tranScatheter Aortic valvE ImplantationItaly
-
Catholic University of the Sacred HeartFrancesca Graziani, MD; Stefano Cangemi, MDRecruitingTranscatheter Aortic Valve Replacement | Lung Ultrasound | Severe Aortic Valve Stenosis | Pulmonary CongestionItaly
-
Medstar Health Research InstituteCompletedAortic StenosisUnited States
-
University Hospital, RouenCompleted
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
RWTH Aachen UniversityCompleted
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
IRCCS Policlinico S. DonatoRecruiting
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Xijing HospitalRecruiting